Last reviewed · How we verify
Artane (TRIHEXYPHENIDYL)
At a glance
| Generic name | TRIHEXYPHENIDYL |
|---|---|
| Sponsor | Lederle |
| Drug class | trihexyphenidyl |
| Target | Muscarinic acetylcholine receptor M1 |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1949 |
Approved indications
- Arteriosclerotic Parkinsonism
- Extrapyramidal disease
- Parkinson's disease
- Parkinsonism
- Postencephalitic parkinsonism
Common side effects
- Dryness of the mouth
- Dizziness
- Mild nausea
- Nervousness
- Blurring of vision
- Constipation
- Drowsiness
- Urinary hesitancy or retention
- Tachycardia
- Dilation of the pupil
- Increased intraocular tension
- Weakness
Key clinical trials
- Anticholinergic Deprescription in Schizophrenia (PHASE4)
- Reduction of Anticholinergic Medications Among Persons With Schizophrenia or Other Psychiatric Disorders (NA)
- Pharmacogenomic Contributions to Trihexyphenidyl Biotransformation and Response in Children With Dystonic Cerebral Palsy (PHASE1)
- a Pilot Study of Pramipexole to Treat Extrapyramidal Symptoms Induced by Antipsychotics (EARLY_PHASE1)
- Excessive Crying in Children With Cerebral Palsy and Communication Deficits (PHASE4)
- Neuroimaging of Dystonia
- Childhood Hypertonia of Central Origin: A Trial of Anticholinergic Treatment Effects (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |